Table 1 Clinicopathologic variables and the expression of FAM83H and Nectin1 in bladder urothelial carcinomas
Characteristics | Total | FAM83H expression | p | Nectin1 expression | p | Combined expression | p | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Positive | Negative | Positive | Negative | FAM83H+/Nectin1+ | FAM83H+/Nectin1− or FAM83H−/Nectin1+ | FAM83H−/Nectin1− | ||||||
All cases | 165 | 110 (66.7%) | 55 (33.3%) | Â | 101 (61.2%) | 64 (38.8%) | Â | 86 (52.1%) | 39 (23.6%) | 40 (24.2%) | Â | |
Sex | Male | 145 | 96 (66.2%) | 49 (33.8%) | Â | 87 (60%) | 58 (40%) | Â | 74 (51%) | 35 (24.1%) | 36 (24.8%) | Â |
| Â | Female | 20 | 14 (70%) | 6 (30%) | 0.736 | 14 (70%) | 6 (30%) | 0.39 | 12 (60%) | 4 (20%) | 4 (20%) | 0.753 |
Age (years) | ≤ 65 | 44 | 25 (56.8%) | 19 (43.2%) |  | 25 (56.8%) | 19 (43.2%) |  | 20 (45.5%) | 10 (22.7%) | 14 (31.8%) |  |
|  | > 65 | 121 | 85 (70.2%) | 36 (29.8%) | 0.106 | 76 (62.8%) | 45 (37.2%) | 0.485 | 66 (54.5%) | 29 (24%) | 26 (21.5%) | 0.377 |
Histologic grade | Low | 56 | 23 (41.1%) | 33 (58.9%) | Â | 21 (37.5%) | 35 (62.5%) | Â | 14 (25%) | 16 (28.6%) | 26 (46.4%) | Â |
|  | High | 109 | 87 (79.8%) | 22 (20.2%) |  < 0.001 | 80 (73.4%) | 29 (26.6%) |  < 0.001 | 72 (66.1%) | 23 (21.1%) | 14 (12.8%) |  < 0.001 |
T stage | Ta | 37 | 18 (48.6%) | 19 (51.4%) | Â | 19 (51.4%) | 18 (48.6%) | Â | 12 (32.4%) | 13 (35.1%) | 12 (32.4%) | Â |
| Â | T1 | 77 | 50 (64.9%) | 27 (35.1%) | Â | 46 (59.7%) | 31 (40.3%) | Â | 39 (50.6%) | 18 (23.4%) | 20 (26%) | Â |
| Â | T2-4 | 51 | 42 (82.4%) | 9 (17.6%) | 0.004 | 36 (70.6%) | 15 (29.4%) | 0.176 | 35 (68.6%) | 8 (15.7%) | 8 (15.7%) | 0.021 |
N stage | N0 | 158 | 104 (65.8%) | 54 (34.2%) | Â | 94 (59.5%) | 64 (40.5%) | Â | 80 (50.6%) | 38 (24.1%) | 40 (25.3%) | Â |
| Â | N1-3 | 7 | 6 (85.7%) | 1 (14.3%) | 0.275 | 7 (100%) | 0 (0%) | 0.031 | 6 (85.7%) | 1 (14.3%) | 0 (0%) | 0.163 |
M stage | M0 | 160 | 105 (65.6%) | 55 (34.4%) | Â | 97 (60.6%) | 63 (39.4%) | Â | 82 (51.3%) | 38 (23.8%) | 40 (25%) | Â |
| Â | M1 | 5 | 5 (100%) | 0 (0%) | 0.108 | 4 (80%) | 1 (20%) | 0.381 | 4 (80%) | 1 (20%) | 0 (0%) | 0.359 |
TNM stage | Stage 0 | 37 | 18 (48.6%) | 19 (51.4%) | Â | 19 (51.4%) | 18 (48.6%) | Â | 12 (32.4%) | 13 (35.1%) | 12 (32.4%) | Â |
| Â | Stage I | 77 | 50 (64.9%) | 27 (35.1%) | Â | 46 (59.7%) | 31 (40.3%) | Â | 39 (50.6%) | 18 (23.4%) | 20 (26%) | Â |
| Â | Stage II, III | 46 | 37 (80.4%) | 9 (19.6%) | Â | 32 (69.6%) | 14 (30.4%) | Â | 31 (67.4%) | 7 (15.2%) | 8 (17.4%) | Â |
| Â | Stage IV | 5 | 5 (100%) | 0 (0%) | 0.008 | 4 (80%) | 1 (20%) | 0.298 | 4 (80%) | 1 (20%) | 0 (0%) | 0.056 |
Recurrence | Present | 49 | 39 (79.6%) | 10 (20.4%) | Â | 37 (75.5%) | 12 (24.5%) | Â | 30 (61.2%) | 16 (32.7%) | 3 (6.1%) | Â |
| Â | Absent | 116 | 71 (61.2%) | 45 (38.8%) | 0.022 | 64 (55.2%) | 52 (44.8%) | 0.014 | 56 (48.3%) | 23 (19.8%) | 37 (31.9%) | 0.002 |